Results 101 to 110 of about 965,597 (282)
Biomarkers in acute coronary syndromes and their role in diabetic patients [PDF]
, 2005 Diabetic patients with acute coronary syndromes are at high risk for cardiovascular complications but risk stratification in these patients remains challenging.
Heeschen, Christopher +1 more
core +1 more source
ARYA Atherosclerosis, 2016 BACKGROUND: High-sensitivity C-reactive protein (hs-CRP) inflammatory biomarker is one of the best informative markers of prognosis of coronary artery disease (CAD) that has been studied.
Seyed Masoud Seyedian +3 more
doaj
The Professional Medical Journal, 2010 Objective: To determine the direct treatment cost of unstable angina (UA) withlow molecular weight heparin (LMWH) in conservative management. Study design: Prospectivestudy. Settings: Government cardiovascular hospital and private tertiary care hospital, Karachi.Study period: One year.
Shazia Alam +3 more
openaire +2 more sources
Journal of Evidence-Based Medicine, EarlyView.ABSTRACT Despite the centrality of syndrome differentiation in guiding personalized traditional Chinese medicine (TCM) interventions for coronary heart disease (CHD), existing studies of TCM syndrome distribution are constrained by fragmented methodologies and limited spatiotemporal resolution. In this study, we employed an artificial intelligence (AI)‐
Qianzi Che +15 more
wiley +1 more source
Евразийский Кардиологический Журнал, 2016 SUMMARY Objective: to assess the impact of cell plasma hemostasis disorders and the level of biomarkers on clinical outcomes and to develop laboratory diagnostic criteria forecast recurrent coronary events in patients with unstable angina.
L. G. Gelis +5 more
doaj +1 more source
Low Weight Loss Response to Incretin Analogs: A Systematic Review
Obesity Reviews, EarlyView.ABSTRACT The development of GLP‐1 and GIP analogs has been a significant breakthrough in type 2 diabetes and obesity pharmacotherapy. However, individual responses to these medications can vary widely. This systematic review examines factors associated with low or no weight loss response to GLP‐1 and GIP analogs. Key predictors of poor response include
Pamela S. Gaskin, Peter S. Chami
wiley +1 more source
Pharmacological management of angina pectoris
, 2021 Ischemic heart disease remains the leading cause of death in adults in the United States despite a decrease in the mortality rate of coronary heart disease in the last four years.
Emma-Okah, Rakel
core
ANALYSIS OF PRE-HOSPITAL TREATMENT OF ACUTE CORONARY SYNDROME
Рациональная фармакотерапия в кардиологии, 2015 Aim. To evaluate the pre-hospital treatment of patients with acute coronary syndromes (acute myocardial infarction and unstable angina) in 2001 and 2006.Material and methods. Retrospective pre-hospital treatment survey was performed in 1114 patients with
O. V. Reshetko +2 more
doaj +1 more source
Obesity Reviews, EarlyView.ABSTRACT Introduction Cardiovascular (CV) outcomes of Glucagon‐like peptide‐1 (GLP‐1)–based medicines among people with overweight and obese (OW/OB) population have been investigated by meta‐analyses of randomized controlled trials (RCTs), but an overall summary is lacking.
Muhammed Rashid +6 more
wiley +1 more source
Unstable angina. The problem of definition
, 1975 Unstable angina is used interchangeably with a variety of other terms to refer to a clinical situation inter-mediate in severity between chronic effort angina and myocardial infarction.
Robert A. Chahine
core